Stock Track | Apogee Therapeutics Soars 5.28% Following Mizuho Securities' Buy Rating and $105 Price Target

Stock Track11-11

Shares of Apogee Therapeutics (APGE) are soaring 5.28% in intraday trading on Tuesday, as investors react positively to a reaffirmed Buy rating from Mizuho Securities. The surge comes after analyst Joseph Catanzaro maintained his bullish stance on the stock and set an ambitious price target of $105.00.

The Mizuho Securities report, released before the market opened, appears to have sparked renewed interest in Apogee Therapeutics. Analyst ratings and price targets often serve as key indicators for investors, potentially influencing trading decisions and stock performance.

While specific details about Apogee Therapeutics' business developments or financial performance were not provided in the available news, the maintained Buy rating and the high price target suggest that Mizuho Securities sees significant upside potential for the company. As the trading session progresses, it remains to be seen whether Apogee Therapeutics can maintain its momentum and close the day near its intraday highs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148776358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 23:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148776358","market":"nz","top_or_hot":-1,"title":"Stock Track | Apogee Therapeutics Soars 5.28% Following Mizuho Securities' Buy Rating and $105 Price Target","media":"Stock Track","content":"<p>Shares of Apogee Therapeutics (APGE) are soaring 5.28% in intraday trading on Tuesday, as investors react positively to a reaffirmed Buy rating from Mizuho Securities. The surge comes after analyst Joseph Catanzaro maintained his bullish stance on the stock and set an ambitious price target of $105.00.</p>\n\n<p>The Mizuho Securities report, released before the market opened, appears to have sparked renewed interest in Apogee Therapeutics. Analyst ratings and price targets often serve as key indicators for investors, potentially influencing trading decisions and stock performance.</p>\n\n<p>While specific details about Apogee Therapeutics' business developments or financial performance were not provided in the available news, the maintained Buy rating and the high price target suggest that Mizuho Securities sees significant upside potential for the company. As the trading session progresses, it remains to be seen whether Apogee Therapeutics can maintain its momentum and close the day near its intraday highs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Apogee Therapeutics Soars 5.28% Following Mizuho Securities' Buy Rating and $105 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Apogee Therapeutics Soars 5.28% Following Mizuho Securities' Buy Rating and $105 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-11 23:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Apogee Therapeutics (APGE) are soaring 5.28% in intraday trading on Tuesday, as investors react positively to a reaffirmed Buy rating from Mizuho Securities. The surge comes after analyst Joseph Catanzaro maintained his bullish stance on the stock and set an ambitious price target of $105.00.</p>\n\n<p>The Mizuho Securities report, released before the market opened, appears to have sparked renewed interest in Apogee Therapeutics. Analyst ratings and price targets often serve as key indicators for investors, potentially influencing trading decisions and stock performance.</p>\n\n<p>While specific details about Apogee Therapeutics' business developments or financial performance were not provided in the available news, the maintained Buy rating and the high price target suggest that Mizuho Securities sees significant upside potential for the company. As the trading session progresses, it remains to be seen whether Apogee Therapeutics can maintain its momentum and close the day near its intraday highs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APGE","symbol_name":"Apogee Therapeutics","start_time":0,"source_url":"","article_id":"1148776358","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148776358","pubTimestamp":1762874538,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Apogee Therapeutics (APGE) are soaring 5.28% in intraday trading on Tuesday, as investors react positively to a reaffirmed Buy rating from Mizuho Securities. The surge comes after analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APGE":"Apogee Therapeutics"},"translate_title":"个股追踪|瑞穗证券给予买入评级和105美元目标价后Apogee Therapeutics股价飙升5.28%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APGE":1},"content_text":"Shares of Apogee Therapeutics (APGE) are soaring 5.28% in intraday trading on Tuesday, as investors react positively to a reaffirmed Buy rating from Mizuho Securities. The surge comes after analyst Joseph Catanzaro maintained his bullish stance on the stock and set an ambitious price target of $105.00.\nThe Mizuho Securities report, released before the market opened, appears to have sparked renewed interest in Apogee Therapeutics. Analyst ratings and price targets often serve as key indicators for investors, potentially influencing trading decisions and stock performance.\nWhile specific details about Apogee Therapeutics' business developments or financial performance were not provided in the available news, the maintained Buy rating and the high price target suggest that Mizuho Securities sees significant upside potential for the company. As the trading session progresses, it remains to be seen whether Apogee Therapeutics can maintain its momentum and close the day near its intraday highs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148776358","isCrawlerRequest":true}